Health Care

The State AG Report – 04.02.2026 is a curated newsletter by Cozen O'Connor summarizing recent state attorneys general (AGs) and federal regulatory actions across the US, published on April 6, 2026.[3][7][11]

The core event is the US military's use of AI to conduct over 1,000 strikes on Iranian targets in the first 24 hours of war, exceeding 3,000 by week's end—twice the "shock and awe" phase of the 2003 Iraq invasion—while U.S. Central Command (Centcom) maintains humans approve every target. This mirrors Israel's Lavender AI system in Gaza, where operators spent ~20 seconds per target, often just confirming the individual was male, reducing human role to approval. In parallel, Cigna's 2023 algorithm led physicians to deny claims in 1.2 seconds on average, with one doctor rejecting 60,000 monthly via batch approvals.[Input]

Miles Mediation & Arbitration published an article on April 6, 2026, advising on when to mediate catastrophic injury cases—defined as permanent, life-altering injuries involving lifelong medical needs, disability, wage loss, and complex causation—versus when to delay for better outcomes[1]. No specific incident, lawsuit, or parties are involved; it's general strategic guidance for plaintiffs, defendants, insurers, and mediators in high-stakes personal injury litigation[1][3].

Mohr Marketing launched a high-precision mesothelioma lead program on April 6, 2026, designed exclusively for plaintiff law firms nationwide. The program uses real-time consumer search intelligence, proprietary data modeling, and strict validation for medical diagnoses (e.g., biopsy-confirmed) and asbestos exposure (e.g., high-risk trades pre-1980s) to deliver intake-ready cases, filtering from ~25,000 monthly searchers into ~73% actionable profiles targeting terms like mesothelioma litigation, asbestos exposure, and FDA treatments such as Pemetrexed (Alimta), Ipilimumab (Yervoy), and Nivolumab (Opdivo).[1][5][6][7]

Chiles v. Salazar is a U.S. Supreme Court case decided on March 31, 2026, in an 8-1 ruling authored by Justice Gorsuch, which held that Colorado's Minor Conversion Therapy Law (MCTL)—banning licensed mental health professionals from providing conversion therapy to minors—regulates speech based on viewpoint when applied to talk therapy, requiring strict scrutiny review rather than rational-basis review.[1][2][4][6] The Court reversed lower court denials of a preliminary injunction sought by petitioner Kaley Chiles and remanded for further proceedings, emphasizing that licensed professionals retain full First Amendment protections and that the law targets expressive content, not just conduct like aversive interventions.[1][5][13]

On April 2, 2026, President Donald Trump issued a Proclamation under Section 232 of the Trade Expansion Act of 1962, imposing a default 100% ad valorem duty on imports of patented pharmaceuticals, active pharmaceutical ingredients (APIs), and key starting materials listed in Annex I, effective July 31, 2026 for large companies in Annex III and September 29, 2026 for others.[1][2][3][5] Reduced rates apply for approved onshoring plans (20% until April 2, 2030), MFN pricing agreements with HHS and Commerce (0% through Jan. 20, 2029), and trade partners like the UK (10%) or EU/Japan/S. Korea/Switzerland/Liechtenstein (15%); generics, biosimilars, and Annex IV products are exempt, with generics review in April 2027.[2][4][5][7]

"Health Care Roundup: Market Talk" on April 7, 2026, compiles analyst insights and discussions on health care sector stocks, focusing on recent financial results and growth prospects for companies like Pro Medicus and Gilead Sciences amid broader industry trends.[9]

Gilead Sciences, a California-based pharmaceutical company (Nasdaq: GILD), announced on April 7, 2026, a definitive agreement to acquire Tubulis GmbH, a Munich-based clinical-stage German biotech, for $3.15 billion in upfront cash plus up to $1.85 billion in milestone payments, totaling potentially $5 billion.[2][4][5] The deal adds Tubulis' next-generation antibody-drug conjugate (ADC) platforms, including the clinically validated Tubutecan linker-payload technology, and assets like TUB-040 (NaPi2b-targeted TOPO1i ADC in Phase 1b/2 for platinum-resistant ovarian cancer and NSCLC, showing 59% response rate in early ovarian data) and TUB-030 (5T4-targeted ADC for solid tumors).[2][4][6][9] Post-close in Q2 2026, Tubulis will operate as a dedicated ADC research hub in Munich, subject to regulatory approvals.[2][5]